Abdominal multi-detector row CT: Effectiveness of determining contrast medium dose on basis of body surface area

作者：Onishi Hiromitsu^*; Murakami Takamichi; Kim Tonsok; Hori Masatoshi; Osuga Keigo; Tatsumi Mitsuaki; Higashihara Hiroki; Maeda Noboru; Tsuboyama Takahiro; Nakamoto Atsushi; Tomoda Kaname; Tomiyama Noriyuki

来源：European Journal of Radiology, 2011, 80(3): 643-647.

DOI：10.1016/j.ejrad.2010.08.037

• Computed tomography
• Contrast medium
• Body surface area
• Aorta
• Liver

Purpose: To investigate the validity of determining the contrast medium dose based on body surface area (BSA) for the abdominal contrast-enhanced multi-detector row CT comparing with determining based on body weight (BW).
Materials and methods: Institutional review committee approval was obtained. In this retrospective study, 191 patients those underwent abdominal contrast-enhanced multi-detector row CT were enrolled. All patients received 96 mL of 320 mg I/mL contrast medium at the rate of 3.2 mL. The iodine dose required to enhance 1 HU of the aorta at the arterial phase and that of liver parenchyma at portal venous phase per BSA were calculated (EU(BSA)) and evaluated the relationship with BSA. Those per BW were also calculated (EU(BW)) and evaluated. Estimated enhancement values (EEVs) of the aorta and liver parenchyma with two protocols for dose decision based on BSA and BW were calculated and patient-to-patient variability was compared between two protocols using the Levene test.
Results: The mean of EU(BSA) and EU(BW) were 0.0621 g I/m(2)/HU and 0.00178 g I/kg/HU for the aorta, and 0.342 g I/m(2)/HU and 0.00978 g I/kg/HU for the liver parenchyma, respectively. In the aortic enhancement, EU(BSA) was almost constant regardless of BSA, and the mean absolute deviation of the EEV with the BSA protocol was significantly lower than that with the BW protocol (P < .001), although there was no significant difference between two protocols in the hepatic parenchymal enhancement (P = .92).
Conclusion: For the aortic enhancement, determining the contrast medium dose based on BSA was considered to improve patient-to-patient enhancement variability.

• 出版日期2011-12